Eupraxia Pharmaceuticals Inc. (EPRX.TO)

CAD 4.59

(-2.34%)

Net Income Summary of Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc.'s latest annual net income in 2023 was -37.39 Million CAD , down -60.76% from previous year.
Eupraxia Pharmaceuticals Inc.'s latest quarterly net income in 2024 Q2 was -8.21 Million CAD , up 26.29% from previous quarter.
Eupraxia Pharmaceuticals Inc. reported an annual net income of -23.25 Million CAD in 2022, down -1.17% from previous year.
Eupraxia Pharmaceuticals Inc. reported an annual net income of -22.98 Million CAD in 2021, down -475.14% from previous year.
Eupraxia Pharmaceuticals Inc. reported a quarterly net income of -8.14 Million CAD for 2024 Q1, down -98.96% from previous quarter.
Eupraxia Pharmaceuticals Inc. reported a quarterly net income of -6.31 Million CAD for 2023 Q3, up 19.33% from previous quarter.

Annual Net Income Chart of Eupraxia Pharmaceuticals Inc. (2023 - 2017)

Historical Annual Net Income of Eupraxia Pharmaceuticals Inc. (2023 - 2017)

Year	Net Income	Net Income Growth
2023	-37.39 Million CAD	-60.76%
2022	-23.25 Million CAD	-1.17%
2021	-22.98 Million CAD	-475.14%
2020	-3.99 Million CAD	44.3%
2019	-7.17 Million CAD	45.77%
2018	-13.23 Million CAD	-206.46%
2017	-4.31 Million CAD	0.0%

Year	Net Income	Net Income Growth
2024 Q2	-8.21 Million CAD	26.29%
2024 Q1	-8.14 Million CAD	-98.96%
2023 Q3	-6.31 Million CAD	19.33%
2023 FY	-38.08 Million CAD	-63.76%
2023 Q4	-4.09 Million CAD	35.13%
2023 Q2	-7.82 Million CAD	-57.81%
2023 Q1	-4.95 Million CAD	43.78%
2022 Q2	-6.09 Million CAD	-65.01%
2022 Q4	-8.82 Million CAD	-89.52%
2022 FY	-23.25 Million CAD	-1.17%
2022 Q1	-3.69 Million CAD	0.74%
2022 Q3	-4.65 Million CAD	23.56%
2021 Q2	-5.43 Million CAD	38.63%
2021 Q4	-3.71 Million CAD	25.25%
2021 Q1	-8.86 Million CAD	-6332.66%
2021 FY	-22.98 Million CAD	-475.14%
2021 Q3	-4.97 Million CAD	8.51%
2020 Q2	-983.23 Thousand CAD	54.18%
2020 FY	-3.99 Million CAD	44.3%
2020 Q4	-137.73 Thousand CAD	87.01%
2020 Q3	-1.06 Million CAD	-7.82%
2020 Q1	-2.14 Million CAD	-192.09%
2019 Q3	-1.74 Million CAD	0.0%
2019 FY	-7.17 Million CAD	45.77%
2019 Q4	-734.63 Thousand CAD	57.9%
2018 FY	-13.23 Million CAD	-206.46%
2017 FY	-4.31 Million CAD	0.0%

Peer Net Income Comparison of Eupraxia Pharmaceuticals Inc.

Name	Net Income	Net Income Difference
Appili Therapeutics Inc.	-3.78 Million CAD	-888.961%
Helix BioPharma Corp.	-9.26 Million CAD	-303.624%
Microbix Biosystems Inc.	-39.48 Thousand CAD	-94603.31%
Medicenna Therapeutics Corp.	-25.46 Million CAD	-46.83%
Satellos Bioscience Inc.	-15.88 Million CAD	-135.331%
Oncolytics Biotech Inc.	-27.75 Million CAD	-34.735%
Sernova Corp.	-38.99 Million CAD	4.118%